This policy brief, including the following “Introduction and Executive Summary,” comes from Eric M. Solovy. CLICK HERE to read the brief in full. Introduction and Executive Summary On June 17, […]
[Archived Post] Panel Discussion: Vaccines, Intellectual Property, and Global Equity
The following post comes from Colin Kreutzer, a 2E at Scalia Law and a Research Assistant at C-IP2. The COVID-19 pandemic has shined a spotlight on the role of intellectual […]
[Archived Post] A View from Both Sides: COVID-19, the TRIPS Waiver, IP Rights, and How to Increase the Supply of Vaccines
Issue The United States and other wealthy nations have access to plenty of COVID-19 vaccine doses and thus are beginning to get the pandemic under control, while less affluent countries […]
[Archived Post] WTO IP Waiver Too Simplistic: Global Vaccine Tech-Transfer Needs Other Strategies
By Yogesh Pai Since October 2020, India and South Africa, joined by two-thirds of the WTO Members (African Group, LDCs and most of developing world) have been actively pursuing other […]
[Archived Post] USPTO-DOJ Workshop on Promoting Innovation in the Life Science Sector: Day Two Recap
The following post comes from Austin Shaffer, a 2L at Scalia Law and a Research Assistant at CPIP. By Austin Shaffer This past fall, the Department of Justice (DOJ) and […]
[Archived Post] IP Industries Step Up in This Time of Crisis
The global COVID-19 pandemic has challenged multiple aspects of modern society in a short time. Health and public safety, education, commerce, research, arts, and even basic government functions have had […]